ClinicalTrials.gg
RecruitingNCT06719440BELGICAUpdated Feb 27, 2026

Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

An interventional study of Radiotherapy (CTV=10mm) and Radiotherapy (CTV=15mm) in Glioblastoma and Radiotherapy Side Effect, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Recruiting at 23 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
347
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Glioblastoma with a site in Belgium — 14 open to participants now, 20 under way, 3 of them phase 3. Glioblastoma · Belgium.

Planned enrollment
12th of 51
347 · median 110
Started
2025
with 4 others
No phase
6 of 58
4 open now
Primary completion
2031-10
later than 19 of 19 live
Registered
54th of 58
by date
Lead sponsor
2 of 58
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Among the 58 studies in Glioblastoma with a site in Belgium, this one is the 12th largest by planned enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2025, is one of 6 with no phase, reaches primary completion later than 19 of the 19 other live ones, and was the 54th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

14 of the 58 studies in Glioblastoma with a site in Belgium are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Glioblastoma with a site in Belgium, or all of them as a file.
02

Study summary

The objective of the BELGICA trial is to evaluate if radiotherapy could be given in a more focused manner in patients with glioblastoma in order to reduce side effects and improve quality of life.

The glioblastoma (GBM) is the most common and aggressive tumour originating from the brain, affecting approximately 600 patients per year in Belgium. The treatment consists in surgical resection of the tumour (when feasible), followed by a combination of radiotherapy and chemotherapy. Despite multimodal treatment (surgery, radiotherapy, and chemotherapy), the life expectancy of patients with GBM remains limited, with an average survival of 12-18 months and only 5% of patients surviving more than 5 years. In addition to limited survival, most patients with GBM experience impaired quality of life, both because of the disease and treatments.

Radiotherapy is a treatment where radiation is used to kill cancer cells. In GBM, radiotherapy is targeted at the tumour (or tumour bed if the tumour was resected) with a safety margin around it (the "Clinical Target Volume" or CTV) to account for potential microscopic spread of the tumour. The downside of this safety margin is that a substantial amount of brain tissue is irradiated, which can lead to treatment toxicity. Reducing the CTV margin would enable to decrease the volume of brain being irradiated and could thereby allow to reduce the side effects of brain irradiation.

The BELGICA trial (Achieving a BEtter outcome through Limiting the GlIoblastoma Clinical tArget volume) is a national multicentre trial which will evaluate if reducing the irradiation volume in glioblastoma is safe and allows for lowering side effects and improving quality of life.

03

Conditions studied

  • Glioblastoma
  • Radiotherapy Side Effect
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants capable of giving
  • Age >= 18 y.o.
  • 0-2
  • Newly diagnosed glioblastoma ( proven glioblastoma per WHO 2021 classification based on or resection )
  • Indication of chemoradiotherapy confirmed by multidisciplinary tumour board

Exclusion criteria

Exclusion Criteria:

  • Participation in a competing trial
  • Known to undergo MRI scans
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
347 participants (estimated)

Study arms

  • Active comparator
    Standard of Care

    Radiation: Radiotherapy (CTV=15mm)

  • Experimental
    Interventional arm

    Radiation: Radiotherapy (CTV=10mm)

Interventions

  • RadiationRadiotherapy (CTV=10mm)

    Radiotherapy with reduced irradiation volume CTV=10mm

  • RadiationRadiotherapy (CTV=15mm)

    Radiotherapy with standard irradiation volume CTV=15mm

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Number of days from date of randomization to the date of death due to any cause

    Time frame: From randomization to the end of the study

Secondary outcomes

  1. Neurocognitive functioning

    Hopkins verbal learning test revised; Trail Marking Test A \& B; Controlled Oral Word Association Test

    Time frame: at baseline, 1 month after radiotherapy and at 1 year

  2. Radiation-induced toxicity

    Assessment of fatigue, headache, nausea, alopecia and radiatio dermatitis according to the CTCAE assessment score. Score ranges from Grade 1 to Grade 5, with higher grades resulting in more severe symptoms.

    Time frame: From enrollment until end of follow-up (2 years)

  3. Health-related Quality of Life

    EQ-5D-5L; QLQ-C30; QLQ-BN20

    Time frame: From enrollment until end of follow-up (2 years)

  4. Progression-free survival

    Length of time during and after treatment for a disease, such as cancer, that a patient lives with the disease without it worsening

    Time frame: From randomization until end of follow-up (2 years)

  5. Pattern of recurrence

    (in case of progression) Manner in which the tumor returns after a period of improvement or remission. It often involves tracking the frequency, timing, and location of the tumor's return

    Time frame: From randomization until end of follow-up (2 years)

  6. Anti-edema therapy

    Recording of the needs of anti-edema therapy

    Time frame: From randomization until end of follow-up (2 years)

Other outcomes

  1. Normal tissue complication probability model (NTCP)

    To develop a normal tissue complication probability model (NTCP) for radiation-induced cognitive toxicity, based on clinical and dosimetric measures (e.g. radiation dose delivered to brain structures)

    Time frame: From enrollment until end of follow-up (2 years)

07

Study locations

18 of 23 sites recruiting
  • Olv Azorg
    Aalst, 9300, Belgium
    Not yet recruiting
    • Secretary office · Contactradiotherapie@azorg.be · +32 53 72 86 66
    • Samuel Bral, MD · Principal investigator
    • Benedikt Engels, MD · Sub investigator
  • EpiCURA
    Baudour, 7331, Belgium
    Recruiting
    • Secretary office · Contact+32 65 61 44 86
    • Serge Ndam, MD · Principal investigator
  • AZ Sint Jan
    Bruges, 8000, Belgium
    Recruiting
  • Institut Jules Bordet
    Brussels, 1070, Belgium
    Not yet recruiting
  • UZ Brussel
    Brussels, 1090, Belgium
    Not yet recruiting
  • Cliniques universitaires Saint-Luc
    Brussels, 1200, Belgium
    Recruiting
    • Secretary office · Contact+32 2 764 47 52
    • Dario Di Perri, MD · Principal investigator
    • Nicolas Whenham, MD · Sub investigator
  • Ziekenhuis Oost-Limburg (ZOL)
    Genk, 3600, Belgium
    Recruiting
    • Secretary office · Contact+32 89 80 83 30
    • Mieke Govers, MD · Principal investigator
    • Annelies Maes, MD · Sub investigator
    • Anne-Sophe Van de Velde, MD · Sub investigator
  • AZ Sint-Lucas
    Ghent, 9000, Belgium
    Recruiting
  • UZ Gent
    Ghent, 9000, Belgium
    Not yet recruiting
  • Grand Hôpital de Charleroi
    Gilly, 6060, Belgium
    Recruiting
    • Secretary office · Contact+32 60 11 12 13
    • Benjamin Ledoux, MD · Principal investigator
  • JESSA Ziekenhuis
    Hasselt, 3500, Belgium
    Recruiting
    • Secretary office · Contact+32 11 33 79 79
    • Anne-Sophe Van de Velde, MD · Principal investigator
    • Annelies Maes, MD · Sub investigator
    • Mieke Govers, MD · Sub investigator
  • AZ Groeninge
    Kortrijk, 8500, Belgium
    Recruiting
    • Secretary office · Contactradiotherapie@azgroeninge.be · +32 56 63 39 03
    • Nick Liefhooghe, MD · Principal investigator
    • Isabelle Kindts, MD · Sub investigator
  • Chu Helora
    La Louvière, 7100, Belgium
    Recruiting
    • Secretary office · Contact+32 64 23 41 88
    • Samuel Palumbo, MD · Principal investigator
  • UZ Leuven
    Leuven, 3000, Belgium
    Recruiting
    • Secretary office · Contact+32 16 34 76 00
    • Maarten Lambrecht, MD · Principal investigator
  • CHU Liège
    Liège, 4000, Belgium
    Recruiting
  • AZ Sint Maarten
    Mechelen, 2800, Belgium
    Recruiting
    • Secretary office · Contact+32 15 89 29 80
    • Julie Van der Veen, MD · Principal investigator
    • Valerie Vandeputte, MD · Sub investigator
  • Hôpital André Vésale - HUmani
    Montigny-le-Tilleul, 6110, Belgium
    Recruiting
    • Secretary Office · Contact+32 71 92 09 52
    • Martin Manderlier, MD · Principal investigator
    • Pauline Semoulin, MD · Sub investigator
  • CH Mouscron
    Mouscron, 7700, Belgium
    Not yet recruiting
  • CHU UCL Namur - Sainte Elisabeth
    Namur, 5000, Belgium
    Recruiting
    • Secretary office · Contact+32 81 72 05 25
    • Marie Wanet, MD · Principal investigator
  • AZ Delta
    Roeselare, 8800, Belgium
    Recruiting
    • Secretary office · Contact+32 51 23 75 82
    • Caroline Sweldens, MD · Principal investigator
    • Lien Van De Voorde, MD · Sub investigator
  • Cliniques de l'Europe
    Uccle, 1180, Belgium
    Recruiting
    • Secretary office (Sainte Elisabeth) · Contact+32 2 614 25 40
    • Secretary office (Saint Michel) · Contact+32 2 614 37 26
    • Dorothée Berben, MD · Principal investigator
  • CHR Verviers
    Verviers, 4800, Belgium
    Recruiting
    • Secretary office · Contact+32 87 21 24 22
    • David Devillers, MD · Principal investigator
  • ZAS Augustinus
    Wilrijk, 2610, Belgium
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Oct 2031, 77 months after the start.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 77 months is above that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Dec 5, 2024
StartActual
May 12, 2025
Primary completionEst.
Oct 2031
CompletionEst.
Oct 2031
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06719440
Collaborators
Belgium Health Care Knowledge Centre
Responsible party
Sponsor
First posted
Dec 5, 2024
Start date
May 12, 2025
Primary completion
Oct 2031 (estimated)
Completion
Oct 2031 (estimated)
Last update
Feb 27, 2026

Study contacts

Dario Di Perri, MD
Contact
dario.diperri@saintluc.uclouvain.be
+32 2 764 47 52
Chloë De Laet
Contact
Belgica.kce@saintluc.uclouvain.be
+32 2 764 82 75
Dario Di Perri, MD
principal investigator · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion